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Rationale: Bronchoscopic lung volume reduction using endobronchial valves is a promising treatment for
severe emphysema patients without collateral ventilation. Physical activity is an important contributing
factor for the autonomy, morbidity and mortality of these patients.
Objective: We investigated the impact of endobronchial valve treatment on physical activity in severe
emphysema patients.
Methods: Physical activity was measured for 7 days by a triaxial accelerometer at baseline and 6 months
follow-up after EBV treatment, and compared with standard medical care in a randomized controlled
trial.
Results: Forty-three patients (77%female, age 59 ± 9years, FEV1 30 ± 7%pred, steps 3563 ± 2213per/day)
wore the accelerometer and were included in the analysis. Nineteen patients received EBV treatment and
24 standard medical care. At baseline, physical activity level was comparable between groups. After 6
months, the endobronchial valve group signiﬁcantly improved compared to the controls in steps/day
(þ1252vs148) and locomotion time (þ17vs2 min/day). Change in sit duration (0vs þ 27 min/day) did
not signiﬁcantly differ.
Conclusions: Physical activity signiﬁcantly improved after endobronchial valve treatment in severe
emphysema patients. This improvement was without any speciﬁc encouragement on physical activity.
Clinical trial number: Dutch trial register: NTR2876.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
We recently showed that bronchoscopic lung volume reduction
using endobronchical valves (EBV) is a promising treatment mo-
dality targeting lung hyperinﬂation for patients with severe
emphysema [1]. The results of this randomized controlled trial
showed that EBV treatment signiﬁcantly improved pulmonary
function, exercise capacity and quality of life after 6 months in
COPD patients characterized by emphysema and the absence of
interlobar collateral ventilation [1].
Potentially, the decrease in lung hyperinﬂation after EBV treat-
ment could reduce dyspnea during exertion and consequently
improve the functional capacity of the body. As dynamic and staticy Diseases AA11, University
roningen, The Netherlands.
.lung hyperinﬂation are independent predictors of daily physical
activity, especially in patients with advanced COPD [2,3], EBV
treatment could potentially improve the patient’s physical activity
level. A higher physical activity level in these patients may improve
the patient’s exercise capacity and lead to restoration of social
participation and a more independent lifestyle. Contrary, in a pilot
study we demonstrated that physical activity did not signiﬁcantly
improve after bronchoscopic lung volume reduction treatment [4].
However, this uncontrolled study had a small sample size and
investigated the bronchoscopic lung volume reduction treatment
with coils instead of endobronchial valves. To our knowledge, the
effect of bronchoscopic lung volume reduction using endobronchial
valves on daily physical activity was not investigated before.
Our aim was to investigate whether daily physical activity in
patients with severe emphysema increases after a bronchoscopic
lung volume reduction treatment using endobronchial valves.
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2.1. Study population and study design
A randomized controlled crossover trial investigating the EBV
treatment was performed in the University Medical Center Gro-
ningen in the Netherlands between June 2011 and November 2014
(STELVIO trial- Dutch trial register: NTR2876 [1]). Patients with
emphysema and a visually determinable treatment target on the
HRCT and proven absence of collateral ventilation between the
target lobe and adjacent lobewere included. The complete list of in-
and exclusion criteria can be found in Table E1 in the online sup-
plement. In total 68 patients were randomized, of which 34 pa-
tients received EBV treatment (‘EBV group’), whereas 34 patients
received standard medical care (‘control group’). After 6 months,
the control group also received the EBV treatment (‘crossover’).
During the study, physical activity was measured by an acceler-
ometer for 7 days at baseline and for 7 days after 6 months follow
up (post randomization and post crossover). The study was
approved by the ethics committee of the University Medical Center
Groningen, and all patients provided informed consent.2.2. Measurements
All measurements were performed at baseline and after 6
months follow-up (post randomization and post crossover). Phys-
ical activity was measured by a triaxial accelerometer (DynaPort,
McRoberts). The accelerometer was worn around the waist at the
lower back. This accelerometer is a highly validated instrument for
evaluating physical activity in patients with COPD [5,6]. Patients
were instructed to wear the accelerometer for 7 days, day and
night, except during showering and swimming. Lung function
Spirometry and bodyplethysmography were performed by blinded
assessors (Jaeger MasterScreen™, CareFusion, Germany) according
to the ATS/ERS guidelines [7e9]. Exercise capacitywas measured by
a 6-minwalk distance (6MWD) test according to the ATS guidelines
[10]. Quality of life was measured by the St. George’s Respiratory
Questionnaire [11]. Dyspnea severitywas measured by the modiﬁed
Medical Research Council (mMRC) scale [12].2.3. Statistical analyses
Patients were included in the analyses if they had worn the
accelerometer for at least 4 full days per assessment, in accordance
with literature [13]. A day was considered a valid measurement day
if the device was worn for at least 94% of the day [14]. When pa-
tients did not want to wear the accelerometer during the night, this
time was recorded as lying. Six patients did not want to wear the
accelerometer during the night and in total for 10 nights the time
not worn was recorded as lying. Furthermore, to be included in the
analyses the patient had to wear the accelerometer for at least 2
times; at baseline and after 6 months follow-up.
Differences between EBV group and control group were tested
with an independent-samples t-test. Baseline and 6 months follow
up measurements were compared with a paired-samples t-test or
Wilcoxon signed-rank test. Pearson correlation coefﬁcients were
calculated to test univariate associations between physical activity
parameters and other clinical parameters. P-values below 0.05
were considered statistically signiﬁcant. Statistical analyses were
performed using IBM SPSS Statistics version 22.3. Results
3.1. Participants
Characteristics of the 43 patients who had evaluable acceler-
ometer data are shown in Table 1 and the ﬂow of patients through
the study is shown in Fig. 1. Of these 43 patients, 19 were treated
with the EBV treatment and 24 patients received standard medical
care. No signiﬁcant differences in clinical characteristics or physical
activity parameters were found between the EBV group and control
group at baseline. After crossover of the control group, 18 patients
also wore the accelerometer 6 months after crossover, leading to 37
patients with evaluable 6 months post EBV treatment data.
3.2. EBV treatment (n ¼ 19) compared to controls (n ¼ 24)
The differences between the EBV group and control group in
change in physical activity and other clinical parameters between
baseline and 6 months follow up are shown in Table 2 and Fig. 2.
The EBV group signiﬁcantly improved compared to the control
group in mean steps per day (þ1252 vs148), locomotion duration
(þ17 vs 2 min per day) and locomotion intensity (þ4.6 vs 1.5%
change compared to baseline). The change in sitting duration (0
vs þ 27 min per day) and inactivity duration (16 vs þ 6 min per
day) did not differ signiﬁcantly between groups. Furthermore, the
EBV group signiﬁcantly improved in spirometry results (FEV1 and
FVC), static hyperinﬂation (RV), dyspnea severity, quality of life and
exercise capacity compared to the control group (Table 2).
3.3. EBV treatment including crossover (n ¼ 37)
The changes in physical activity and other parameters between
baseline and 6 months follow up including the crossover patients
are shown in Table 3. The individual patient data of the change in
steps per day is shown in Fig. 3. After EBV treatment patients
signiﬁcantly improved compared to baseline in steps per day
(mean þ 1133, 95%CI 711e1556), locomotion duration (mean þ 16,
95%CI 9.3e21.9 min/day) and locomotion intensity (þ3.1% change
compared to baseline). Sitting duration (mean 10.5, 95%CI e36.5;
15.6 min/day) and inactivity duration (mean 16.2, 95%CI e39.6;
7.3 min/day) did not signiﬁcantly change 6 months after EBV
treatment.
3.4. Association between physical activity and other clinical
variables
The univariate associations between physical activity parame-
ters and other clinical variables are shown in Table E2 in the online
supplement.
In the population including the EBV group and crossover EBV
group (n ¼ 37) change in steps per day was not signiﬁcantly asso-
ciated with change in other clinical variables.
4. Discussion
To our knowledge, this was the ﬁrst study that measured
physical activity before and after EBV treatment in patients with
severe COPD. Our results showed that physical activity signiﬁcantly
improved 6 months after EBV treatment with a difference in
improvement in physical activity by 1340 steps per day between
the EBV group and the control group.
A recent paper of Waschki et al. showed that patients in GOLD
stage III to IV loose approximately 450 steps per year [15].
Comparing our results with this study means that the difference in
improvement in steps per day of 1340 in our study corresponds to
Table 1
Patient characteristics.
EBV treatment group (n ¼ 19) Control group (n ¼ 24)
Male, n (%) 6 (32%) 4 (17%)
Age, years 59 ± 10 59 ± 7.4
BMI, kg/m2 25.7 ± 4.6 24.1 ± 4.0
FEV1, %pred 31.7 ± 7.8 29.5 ± 7.1
FVC, %pred 79.7 ± 13.2 78.4 ± 19.1
RV, %pred 210 ± 28 219 ± 33
RV/TLC, % 57.9 ± 8.0 60.8 ± 8.1
SO2, % 94.6 (90e97.9) 94.1 (88.2e96.8)
mMRC, score 2.4 ± 0.7 2.7 ± 0.6
SGRQ, total score 52.5 ± 11.9 59.4 ± 12.6
EQ5D, vas score 52.5 ± 15.7 52.4 ± 16.3
CCQ, total score 2.6 ± 0.7 2.7 ± 0.6
6MWD, meter 366 ± 82 388 ± 74
Steps, mean per day 3483 (714e11352) 2982 (964e7808)
Walk intensity, g 0.173 ± 0.029 0.169 ± 0.023
Locomotion duration, %/day 4.7 ± 2.5 4.5 ± 2.3
Sit duration, %/day 40.3 ± 9.9 38.9 ± 8.3
Inactivity duration, % day 83.3 ± 5.9 82.8 ± 5.9
Physiotherapist training  2/week, n (%) 15 (79%) 20 (83%)
Pulmonary rehabilitation <24 months, n (%) 9 (47%) 13 (54%)
Data are presented as n (%), mean ± sd or median (range).
BMI: Body mass index; FEV1: Forced Expiratory Volume in 1 s, FVC: Forced vital capacity, RV: Residual volume, TLC: Total lung capacity, SO2: Oxygen saturation,
mMRC: medical Modiﬁed Research Council, SGRQ: St. George’s Respiratory Questionnaire, EQ5D: EuroQol 5D questionnaire; CCQ: Clinical COPD Questionnaire,
6MWD: 6-min walk distance.
Fig. 1. Flowchart of participant ﬂow through the study.
Table 2
Difference between EBV treatment group and control group in change in physical activity and other clinical characteristics at 6 months FU.
EBV treatment (n ¼ 19) group Control group (n ¼ 24) Between group
D absolute change D % change D absolute change D % change Difference p-value
Steps, mean per day 1252 ± 1468 57.1 ± 73.3 148 ± 862 1.2 ± 18.8 1340 ± 380 0.001
Locomotion duration, %/day 1.15 ± 1.46 36.4 ± 49.7 0.13 ± 0.93 1.6 ± 16.6 1.28 ± 0.37 0.001
Walk intensity, g 0.0067 ± 0.0141 4.6 ± 8.4 0.0028 ± 0.008 1.5 ± 4.6 0.00948 ± 0.0036 0.014
Sit duration, %/day 0.01 ± 6.1 1.44 ± 19.0 1.88 ± 3.0 5.22 ± 8.2 1.86 ± 1.52 0.230
Inactivity duration, min day 1.1 ± 3.2 1.3 ± 3.9 0.39 ± 3.0 0.62 ± 3.65 1.49 ± 0.95 0.126
FEV1, ml 173 ± 226 25.1 ± 28.5 22.5 ± 95.8 3.2 ± 10.9 150 ± 51 0.005
FVC, ml 472 ± 572 21.5 ± 27.7 69.2 ± 365.0 3.6 ± 14.4 403 ± 144 0.008
RV, ml 880 ± 517 20.1 ± 11.4 40.8 ± 265.6 0.5 ± 6.0 838 ± 122 <0.001
mMRC, score 0.58 ± 0.69 21.9 ± 24.9 0.04 ± 0.46 0.69 ± 17.4 0.54 ± 0.18 0.007
SGRQ, total score 15.7 ± 16.3 27.6 ± 28.0 3.0 ± 9.1 3.7 ± 13.7 12.7 ± 4.2 0.005
6MWD, meter 84.5 ± 62.1 26.4 ± 22.0 19.5 ± 35.4 5.1 ± 10.4 104.0 ± 16.3 <0.001
Data are presented as mean ± sd. D absolute change: absolute change between 6months follow up and baseline, D % change: relative change between 6months follow up and
baseline, g: average body acceleration. Difference between groups in D absolute change were tested with an independent-samples t-test. Signiﬁcant values (p < 0.05) are
depicted in bold. FEV1: Forced Expiratory Volume in 1 s, FVC: Forced vital capacity, RV: Residual volume, mMRC: medical Modiﬁed Research Council, SGRQ: St. George’s
Respiratory Questionnaire, 6MWD: 6-min walk distance.
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more, the improvement exceeds the recently established minimal
important difference (MID) for steps per day of 600e1100 [16].In contrast to the pilot study with coils [4], the current study did
demonstrate signiﬁcant improvements in daily physical activity
after treatment with endobronchial valves. The pilot study
Fig. 2. Change between baseline and 6 months follow up in steps per day, locomotion time and sitting time in EBV group and the control group. Bars represent means and standard
deviations.
Table 3
Change in clinical characteristics at 6 months after EBV treatment (n ¼ 37).
Baseline 6-month follow up p-value D relative change
Steps, mean per day 3456 ± 2216 4589 ± 2493 <0.001 47.5 ± 56.9%
Locomotion duration, %/day 4.6 ± 2.5 5.6 ± 2.6 <0.001 34.4 ± 41.8%
Walk intensity, g 0.170 ± 0.026 0.174 ± 0.025 0.040 3.1 ± 7.6%
Sitting duration, %/day 40.9 ± 9.2 40.2 ± 9.8 0.421 1.1 ± 15.7%
Inactivity duration, min day 83.1 ± 5.4 82.0 ± 7.1 0.171 1.3 ± 6.0%
FEV1, %pred 31.1 ± 7.8 38.4 ± 8.8 <0.001 25.6 ± 21.3%
FVC, %pred 80 (54e110) 96 (57e135) <0.001* 17.6 (15e58)%
RV, %pred 216 (161e273) 170 (108e251) <0.001* 18.0 (44.7e5.48)%
mMRC, score 2.5 ± 0.65 2.0 ± 0.65 <0.001 16.9 ± 21.9%
SGRQ, total score 54.2 ± 10.3 40.1 ± 15.8 <0.001 24.9 ± 26.6%
6MWD, meter 366 ± 82 433 ± 74 <0.001 21.3 ± 18.6%
Data are presented as mean ± sd or median (range). Differences between baseline and 6 months follow up were tested with a paired-samples t-test or *Wilcoxon signed rank
test. Signiﬁcant values (p < 0.05) are depicted in bold.
D relative change: relative (%) change between baseline and 6 months follow up.
FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, RV: residual volume, mMRC: modiﬁed Medical Research council scale, SGRQ: St. George’s respiratory
questionnaire, 6MWD: 6-min walk distance.
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sample size (n ¼ 14) and the number of steps only increased on
average 400 steps per day 6 months after the treatment. The reason
for this difference could be a less effective treatment as also the
changes in other clinical parameters, like lung hyperinﬂation and
exercise capacity were less pronounced after treatment with coils.
Furthermore, the patients in the study who were treated with coils
were one of the ﬁrst patients ever treated and a best-responder
proﬁle for this treatment is not deﬁned yet. Currently, there is
more knowledge on the group of patients that will potentially
beneﬁt of the treatment with valves than with the treatment with
coils.
If we compare our EBV treatment effects on physical activity
with those of pharmacological treatment or pulmonary rehabili-
tation we must keep in mind that we selected very severe
emphysema patients, yet ﬁt enough to undergo EBV treatment.
Four randomized controlled trials investigating a long-acting
bronchodilator showed inconsistent results regarding physical ac-
tivity in patients with mainly moderate COPD. Two studies did not
ﬁnd a signiﬁcant improvement in physical activity after 3 weeks or
24 weeks of treatment in contrast to two studies with 3 weekfollow up demonstrating signiﬁcant improvement in number of
steps (722 steps per day) and moderate intensity daily activity
(10.1 min per day) compared to a placebo group [17e20]. The re-
sults of the effect of pulmonary rehabilitation on physical activity is
inconsistent and a review concluded that exercise training (not only
rehabilitation) has a small but signiﬁcant effect on physical activity
[21,22].
Our results showed that physical activity signiﬁcantly improved
after EBV treatment in the short term up to 6 months after treat-
ment and it would be interesting to also investigate the effects on
the longer term. To maintain the effects in the long term, or even
further improve them, it could be useful to provide a physical ac-
tivity enhancement program after the EBV treatment, for example
by following a pulmonary rehabilitation program. Furthermore,
physical activity counselling programs focusing on physical activity
in daily life showed promising results [23,24] and these programs
could also be useful to sustain the effects in the long term.
In the total group receiving EBV treatment (including crossover
patients) we found no signiﬁcant associations between changes in
physical activity and changes in lung function, exercise capacity or
quality of life. Therefore, a larger decrease in hyperinﬂation is not
Fig. 3. Individual patient data at baseline and 6 month follow up for steps per day. For
the control group, baseline was 6 months after randomization.
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activity. Probably other factors play a role as well in the size of the
improvement in physical activity after the EBV treatment. These
factors could be psychological factors such as motivation or self-
efﬁcacy and/or chronic deconditioning, atrophic muscles or the
patient’s history of physical activity. A physical activity enhance-
ment program after the EBV treatment could target these factors as
well to increase the physical activity level even more.
We found that sitting time decreased by 11 min per day and the
EBV group did not signiﬁcantly differ in the change in sitting time
compared to the control group. Sitting time has been associated
with an increased risk of mortality, even independent of leisure
time physical activity [25]. Furthermore, sedentary time has shown
to be an independent risk factor for several health outcomes like
cardiovascular risk factors, independently of physical activity [26].
Breaking-up sitting time could be beneﬁcial, as it was shown to be
beneﬁcially associated with metabolic risk variables and physical
function [27e29]. Therefore, it could be important to also pay
attention to break-up sitting time besides enhancing physical ac-
tivity after the EBV treatment.
A limitation of our study was the relative small sample size, but
we did have a control group which strengthens our ﬁndings.
Another limitation is the high number of patients who were lost to
follow up. However, there were no differences in baseline physical
activity parameters between the patients who were lost to follow
up and the patients included in the analyses (data not shown). A
large trial, ideally sham-controlled, would be useful to conﬁrm our
results. Furthermore, we only measured physical activity 6 monthsafter the treatment and consequently physical activity was
measured during 2 different seasons, which could strongly inﬂu-
ence physical activity. On the other hand, both EBV and control
group patients were measured throughout the year. Ideally, phys-
ical activity should be measured multiple times throughout 1 year
including all seasons. Finally, it should be acknowledged that a
large proportion of the study population were women.
The primary outcomes of most of the randomized controlled
trials investigating a lung volume reduction treatment modality in
patients with severe COPD are pulmonary function or exercise ca-
pacity (e.g. NETT [30], VENT [31], RENEW (NCT01608490) and
LIBERATE (NCT01796392)). Such outcome variables are important
to understand and prove the mechanistic beneﬁts of lung volume
reduction treatment, but ultimately we need patient-centered
outcomes to show that the treatment is also beneﬁcial in the
perception of the patient. In this perception the RESET trial
demonstrated that quality of life improved after the coil treatment
[32]. Another important patient-centered outcome would be
physical activity which has been shown to be associated with
decreased dyspnea severity, improved muscle function, improved
quality of life and decreased risk of mortality in patients with COPD
[33e36]. Furthermore, physical activity is an important prerequi-
site for an independent lifestyle and social participation. Therefore,
we put forward that physical activity should be considered as an
important clinical outcome variable in clinical trials investigating
treatments for severe COPD.
In conclusion, we found that daily physical activity signiﬁcantly
improved 6 months after bronchoscopic lung volume reduction
treatment using one-way endobronchial valves. This improvement
was without any speciﬁc encouragement on physical activity.
Therefore, it would be very interesting to investigate the potential
additional effect when combining the EBV treatment with a phys-
ical activity counselling program or pulmonary rehabilitation
program.
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